Analysts Anticipate Agios Pharmaceuticals (AGIO) Will Post Quarterly Sales of $13.02 Million

Equities analysts expect Agios Pharmaceuticals (NASDAQ:AGIO) to report sales of $13.02 million for the current quarter, according to Zacks. Three analysts have made estimates for Agios Pharmaceuticals’ earnings, with the highest sales estimate coming in at $14.45 million and the lowest estimate coming in at $11.10 million. Agios Pharmaceuticals reported sales of $11.35 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.7%. The firm is expected to issue its next earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $87.79 million for the current fiscal year, with estimates ranging from $51.60 million to $155.90 million. For the next year, analysts expect that the firm will post sales of $264.60 million per share, with estimates ranging from $81.01 million to $600.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.03). Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The firm had revenue of $8.80 million during the quarter, compared to analyst estimates of $11.93 million. During the same period in the previous year, the company posted ($1.56) EPS. Agios Pharmaceuticals’s revenue for the quarter was down 16.2% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the company. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 17th. ValuEngine upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Credit Suisse Group set a $95.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, April 11th. BidaskClub upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Finally, SunTrust Banks set a $115.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $88.40.

In related news, insider Steven L. Hoerter sold 2,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $78.63, for a total transaction of $161,191.50. Following the completion of the transaction, the insider now directly owns 2,050 shares of the company’s stock, valued at approximately $161,191.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction on Monday, May 7th. The stock was sold at an average price of $81.81, for a total value of $245,430.00. Following the transaction, the insider now directly owns 2,881 shares of the company’s stock, valued at $235,694.61. The disclosure for this sale can be found here. Insiders sold a total of 62,950 shares of company stock valued at $5,102,838 over the last quarter. 3.02% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in AGIO. Lord Abbett & CO. LLC raised its position in Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock worth $85,407,000 after purchasing an additional 665,684 shares during the last quarter. Baillie Gifford & Co. acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth about $47,607,000. BlackRock Inc. grew its holdings in Agios Pharmaceuticals by 14.0% during the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock worth $262,192,000 after acquiring an additional 393,336 shares during the period. Point72 Asset Management L.P. grew its holdings in Agios Pharmaceuticals by 343.8% during the 1st quarter. Point72 Asset Management L.P. now owns 406,090 shares of the biopharmaceutical company’s stock worth $33,210,000 after acquiring an additional 314,590 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in Agios Pharmaceuticals by 965.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock worth $19,740,000 after acquiring an additional 312,878 shares during the period. 93.99% of the stock is owned by institutional investors and hedge funds.

NASDAQ:AGIO traded down $0.81 during trading hours on Friday, reaching $86.18. 118,908 shares of the company were exchanged, compared to its average volume of 528,948. The company has a market capitalization of $5.01 billion, a P/E ratio of -12.77 and a beta of 1.98. Agios Pharmaceuticals has a 1-year low of $45.96 and a 1-year high of $89.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply